• Ritadine is longer acting compared to cimetidine and is five to ten times more potent than cimetidine.
• Ritadine provides fast and prompt relief from pain and discomfort .
• Ritadine has smaller doses as compared to cimetidine thus proving its superiority.
• Ritadine is free from anti androgenic effects such as gynaecomastia (in Men) and galactorrhea (in Women) have been reported with cimetidine.
• Ritadine's therapeutic dose does not appear to inhibit oxidative metabolism of other drugs.

Ritadine is 50% absorbed after oral administration, with mean peak levels of 440 to 545 mg/ ml occurring at 2 to 3 hours after a 150 mg dose.
The elimination half life is 2.5 to 3 hours, absorption is not significantly impaired by administration of food or antacid. The principle route of excretion is the urine, with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours. Renal clearance is about 410 ml/ min indicating active tubular excretion , in man the N.Oxide is the principle metabolite in the urine: however, this amount to <40% of the dose. Other metabolites are the S-oxide (1%), and the desmethyl ranitidine (1%), the remainder administered dose is found in the stool.
Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor but clinically insignificant, alterations in rentidine half life, distribution, clearance and bioavailibility.
The volume of distribution is about 1.4L/kg, serum protein binding averages 15%.

1. Short term treatment of active duodenal ulcer.
2. maintainance threapy of duodenal ulcer.
3. Zollinger-ellison syndrome.
4. Short term treatment of benign gestric ulcer.
5. Maintenance threapy of gasric ulcer patients at reduced dosages after healling of acute ulcers.
6. Treatment of GERD.
7. Treatment of endoscopically diagnosed erosive oesophagitis.
8. Maintenance of healling of erosive oesophagitis.
9. Duodenal ulcer associated with helico bacter pylori infection.
10. Chronic episodic dyspepsia.

1. Active duodenal ulcer:- Ritadine 150 mg 1 tablet twice daily forat least 4 week, or 2 tablets Ritadine 150 mg once daily after evening meal or at bed time for at least 4 weeks.
   
   
2. Maintenance Threapy for duodenal ulcer:- Ritadine 150 mg or 1 tablet at bed time.
   
   
3. Zollinger - Ellision Syndrome:- Ritadine 150 mg or 1 tablet twice daily untill necessary.
   
   
4. Short term treatment of benign gastri culcer:- Ritadine 150 mg or 1 tablet twice daily at least 6 weeks.
   
   
5. Maintenance threapy of gastric ucler:- Ritadine 150 mg or 1 tablet at bed time.
   
   
6. Treatment of GERD:- Ritadine 150 mg or 1 tablet twice daily or 2 tablets once daily at bed time for upto 8 weeks and if required 12 weeks.
   
   
7. Erosive oesophagiti:- Ritadine 150 mg or 1 tablet 4 time a day.
   
   
8. Maintenance of erosive oesophagitis:- Ritadine 150 mg or 1 twice daily.
   
   
9. Duodenal ulcer associated with helico bacter pylori infection.:- Ritadine 150 mg or 1 twice daily or two tablets once daily may be given with combination with Amoxycillin 750 mg Metronidazole 500 mg both three time daily for two weeks. Threapy with Ritadine should then be continued for further 2 weeks.
   
   
10. Chronic episodic dyspepsia.:- Ritadine 150 mg or 1 twice daily for upto 6 weeks & for short termsymptomatic relief of dyspepsia, Ritadine 150 mg or 1 tablet twice daily up to 2 weeks.
    
    For Children:
    
    A suggested dose for the treatment of peptic ulcer in children is 2 to 4 mg per kg body weight twice daily to a maximum of 300 mg in 24 hours.

Ritadine is contra-indicated for patients known to have hypersensitivity to the drug or any of the ingredient.

Headach, rarely malaise, dizziness, insomnia and vertigo, rare cases of reversible mental confusion, agitation, depression and hallucination have been reported. As with other H2 blockers are reports of arrhythmias such as tachycardia, bradycardia atro ventricular block and premature ventricular beats.
Constipation, diarrhoea, nausea / vomiting, abdominal discomfort/pain and rare reports of pancreatitis. There have been occasional reports of hepatitis, or hepato canalicular or mixed with or without jaundice. In such circumstances Ritadine should be immediately discontinued. There are rare reports of arthralgia and myalgia.
Reversible blood count changes have occurred in few patients. No stimulation of any pituitary hormones by Ritadine and no antiandrogenic activity, no cimetidine induced gynaecomastia and no impotence in hypersecretory patients have resolved when Ritadine has been substituted, however occasional cases of gynaecomastia, impotence and loss of libido have been reported in male patients receiving Ritadine, but the incidence did not differ from that in the general population.

Unlike cimetidine, ranitidine does not seem to effect cytochrome P450 to any great extent and therefore is considered to have little effect on metabolism of other drugs.
Absorption of ranitidine is reported to be impaired by administration of sucralfate concomitantly.